Xin Lang Cai Jing·2025-12-09 11:49Core Viewpoint - Fosun Pharma announced a licensing agreement with Pfizer for the exclusive global development, use, production, and commercialization rights of GLP-1R agonists, including YP05002, for all human and animal indications [1] Group 1: Agreement Details - The agreement involves Fosun Pharma's subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., and Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. [1] - Yaoyou Pharmaceutical will complete Phase I clinical trials of YP05002 in Australia and grant Pfizer exclusive rights for further global development and commercialization [1] Group 2: Financial Aspects - Yaoyou Pharmaceutical will receive an upfront payment of $150 million [1] - The company is eligible for milestone payments up to $1.935 billion related to specific development, registration, and commercial milestones, along with tiered royalties after product approval [1]